EUCAIM Success Stories: SYCAI’s Journey Towards Robust Clinical AI Validation

Access to diverse, high-quality cancer imaging data remains one of the greatest challenges for European companies developing trustworthy AI for healthcare. Through the EUCAIM platform, SYCAI, a European MedTech SME specializing in AI solutions for abdominal imaging, is leveraging federated access to multi-centre datasets to validate and strengthen its CE-marked AI tools for hepatic and pancreatic disease detection.

A Streamlined Data User Experience

According to SYCAI, EUCAIM’s federated search capabilities have significantly simplified the process of identifying suitable cohorts across multiple data providers. By allowing searches by cancer type and imaging modality, the platform provides a single point of access to datasets that would otherwise require extensive individual outreach.

 

The centralized negotiation workflow has been especially valuable, enabling transparent communication with each data provider while allowing several access requests to be managed simultaneously. Interactions with providers such as INCISIVE have also helped SYCAI refine study designs, inclusion criteria, and technical requirements for federated execution.

Identifying Relevant Datasets Across Europe

SYCAI identified and requested access to eight datasets from three leading European cancer imaging initiatives through EUCAIM:

For SYCAI, the most valuable resources are contrast-enhanced abdominal CT studies accompanied by clinical information and, where available, expert annotations. Since patients with colorectal, prostate, and lung cancer routinely undergo CT examinations that include the liver and pancreas, these datasets provide an important opportunity to validate AI tools on large, real-world, multi-centre populations. The EuCanImage CRLM datasets are particularly relevant for advancing liver lesion detection capabilities.

"EUCAIM gives European innovators something that was missing: a trusted, federated route to diverse cancer imaging data. For SYCAI, it is a key step towards demonstrating that our AI for abdominal cancer detection can perform reliably across diverse patients, hospitals and clinical settings in Europe."
Javier García López, PhD
Co-founder and CTO, SYCAI Medical

Expected Impact

SYCAI anticipates several important outcomes in the future:

 

  • Independent multi-centre validation of its CE-marked liver and pancreas AI tools on populations not represented in the original training data.

 

  • Stronger post-market clinical evidence to support clinical follow-up activities and future regulatory submissions.

 

  • New scientific publications focusing on AI generalisation, uncertainty quantification, and calibration. This work will build upon SYCAI’s CURVAS Challenge at MICCAI 2024 and the resulting publication in Computers in Biology and Medicine (2025)

 

  • New collaborations with data providers, researchers, and clinical partners across the EUCAIM ecosystem. SYCAI has also applied to the AI-BOOST Challenge 3 on generative AI for clinical datasets.

Why EUCAIM Matters for AI Innovation

For SMEs developing AI-powered medical technologies, obtaining access to diverse imaging data remains one of the largest barriers to creating clinically robust and regulatory-compliant solutions.

 

SYCAI highlights that EUCAIM provides a legitimate and well-governed route to accessing multi-centre data that would otherwise take years of individual agreements to secure. The platform’s federated approach allows algorithms to be brought to the data rather than moving data across institutions, supporting compliance with GDPR as well as SYCAI’s ISO 27001 and ISO 42001 information security and AI management processes.

 

This approach is essential for demonstrating that AI tools can perform consistently across different countries, healthcare systems, scanners, and acquisition protocols, generating the evidence needed to support CE-marked medical devices under the EU Medical Device Regulation (MDR).

Building Europe's Future Cancer Imaging Infrastructure

AI in cancer imaging can only deliver meaningful benefits to patients when models are trained and validated on data that reflects the diversity of Europe’s populations, healthcare institutions, and imaging equipment.

 

By providing a secure, trustworthy, and federated infrastructure for cancer imaging research, EUCAIM is helping lower barriers for SMEs, researchers, and innovators while promoting reproducible science and responsible AI development. Through initiatives such as SYCAI’s validation efforts, the platform is supporting the transition from promising AI prototypes to clinically validated tools capable of improving cancer detection and patient care across Europe.

Learn more about becoming a data user

Explore the EUCAIM catalogue

Join the EUCAIM Consortium

Open Call for New Beneficiaries

We’re inviting new partners to enhance our pan-European infrastructure for cancer images and artificial intelligence.

Whether you’re a data holder with valuable cancer images or an innovator developing AI tools for precision medicine, this is your chance to contribute to a groundbreaking project.

Apply by 10 June 2024!

Open Call Webinar

We recently hosted a webinar with more details for prospective applicants to the open call. A recording is available.

Our open Call for new collaborators
launches in April 2024

Opportunities for data holders & AI developers to contribute await! Let‘s join forces to enhance cancer diagnosis and treatment

Be the first to know and apply!

SAVE THE DATE
March 14, 10:00-11:30 aM CET

DISCOVER THE CANCER IMAGE EUROPE PLATFORM

TECHNICAL DEMONSTRATION WEBINAR

Explore the potential for AI-driven cancer care advancements!
Learn how to access and utilize our federated cancer image repository. The webinar is for AI Innovators & Data Providers interested in the platform and will feature an introduction to EUCAIM & Cancer Image Europe and a demonstration of data exploration & access.

Survey Invitation

Join Leading Experts In Shaping AI In Cancer

EUCAIM is looking for your feedback! We have recently published a Stakeholder Survey in order to reach out to potential end-users and stakeholders. We believe that your insights could significantly contribute to understanding the expectations of potential users and identifying the essential aspects that stakeholders find crucial for future engagement and collaboration with the platform.

Therefore, we would like to invite you to participate in the Stakeholder Survey about the Cancer Image Europe platform.

Completing the survey will take approximately 10 minutes. Your participation is crucial to the success of this project, and we deeply appreciate your expertise in shaping the future of cancer imaging and treatment.